Ignite Creation Date:
2024-05-06 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 2:13 PM
Study NCT ID:
NCT05041972
Status:
WITHDRAWN
Last Update Posted:
2022-09-13
First Post:
2021-09-03
Brief Title:
ARX788 in Selected HER2-mutated or HER2-amplifiedOverexpressed Solid Tumors ACE-Pan Tumor-02
Sponsor:
Ambrx Inc
Organization:
Ambrx Inc
Study Overview
Official Title:
A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplifiedOverexpressed Solid Tumors
Status:
WITHDRAWN
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Business strategy change
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplifiedoverexpressed Solid Tumors ACE-Pan tumor-02
Detailed Description:
The study will enroll subjects with HER2-mutated or HER2-amplifiedoverexpressed locally advanced or metastatic solid tumor cancers whose prior standard of care therapies have failed This basket trial will evaluate ARX788 across multiple cancer populations as defined by HER2 genetic biomarkers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None